Sponsor:
Abramson Cancer Center at Penn Medicine
Code:
NCT05733715
Conditions
Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
Pembrolizumab infusion
Lenvatinib tablet
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-03-03.